What are alternative topical treatments to desonide cream for facial eczema when desonide is unavailable?

Alternative Topical Treatments for Facial Eczema When Desonide is Unavailable

For facial eczema when desonide is on backorder, use pimecrolimus 1% cream twice daily as your first-line alternative, or tacrolimus 0.03% ointment twice daily if more potent control is needed. Both topical calcineurin inhibitors (TCIs) are specifically recommended for facial use and avoid the atrophy risk associated with topical corticosteroids 1.

Primary Alternatives: Topical Calcineurin Inhibitors

Pimecrolimus 1% Cream

• Strongly recommended by AAD guidelines for mild-to-moderate atopic dermatitis with high certainty evidence 1
• Particularly well-suited for facial application due to no risk of skin atrophy
• Apply twice daily to affected areas
• Significantly reduces itch (NRS scores 0-1) with RR 2.09 (95% CI: 1.58-2.75) 1
• Decreases flares and reduces need for topical corticosteroid use—one trial showed mean 152 days without TCS use versus 138.7 days with vehicle (P < .001) 1
• Most common side effect: Application-site reactions (burning/stinging), which typically diminish after first week of use 2

Tacrolimus 0.03% Ointment

• Strongly recommended with high certainty evidence for atopic dermatitis 1
• More potent than pimecrolimus; use when facial eczema is moderate-to-severe
• Apply twice daily
• Ranked among most effective treatments in network meta-analysis for both patient-reported symptoms (SMD -1.57) and clinician-reported signs (SMD -2.69) 2
• Also causes application-site reactions but no atrophy risk 1, 2

Secondary Alternatives: Low-Potency Topical Corticosteroids

If TCIs are unavailable or not tolerated due to application-site reactions:

Hydrocortisone 1% or 2.5% Cream

• Class VII (very low potency) or Class VI (low potency)
• Safe for facial use with lower atrophy risk than desonide
• Apply twice daily
• Guidelines emphasize using lowest potency needed for facial/neck areas 1
• Can be used for longer courses than higher-potency steroids due to favorable adverse event profile 1

Newer Non-Steroidal Options

Roflumilast 0.15% Cream (PDE-4 Inhibitor)

• Strongly recommended in 2025 AAD focused update 3
• Apply once daily
• Lower efficacy than TCIs or potent TCS in network meta-analyses 2
• Minimal application-site reactions compared to TCIs
• Consider as third-line option for mild facial eczema

Crisaborole 2% Ointment (PDE-4 Inhibitor)

• FDA-approved for mild-to-moderate atopic dermatitis
• Apply twice daily
• Ranked among least effective treatments in multiple network meta-analyses 2
• Higher application-site reaction rate (OR 2.12,95% CI 1.18-3.81) 2
• Reserve for cases where other options have failed or are contraindicated

Clinical Algorithm for Selection

Step 1: Start with pimecrolimus 1% cream twice daily for most facial eczema cases

• Excellent safety profile for facial skin
• No atrophy risk with long-term use
• Effective for maintenance therapy

Step 2: If inadequate response after 2 weeks, switch to tacrolimus 0.03% ointment twice daily

• More potent anti-inflammatory effect
• Still safe for facial application

Step 3: If TCIs cause intolerable burning/stinging (usually resolves in 1 week), use hydrocortisone 2.5% cream twice daily

• Short-term use (2-4 weeks) to control active flare
• Monitor for atrophy with prolonged use

Step 4: For maintenance after achieving control, continue pimecrolimus 1% or switch to twice-weekly application to prevent relapses

Critical Safety Considerations

Regarding TCI "Black Box Warning"

The FDA black box warning about cancer risk with TCIs concerns many clinicians, but long-term safety studies show increased relative risk of lymphoma but not other cancers, with low absolute risk that is not clinically meaningful 1. This should not deter appropriate facial use.

Avoid These Pitfalls

• Do not use moderate-to-potent TCS on the face (desonide is already low-potency; anything stronger risks atrophy)
• Do not stop TCIs prematurely due to initial burning—this typically resolves within 3-7 days
• Do not use occlusive dressings with any facial treatment 4
• Reassess diagnosis if no improvement within 2 weeks 4

Application-Site Reactions

TCIs rank highest for causing local reactions: tacrolimus 0.1% (OR 2.2), tacrolimus 0.03% (OR 1.51), and pimecrolimus 1% (OR 1.44) 2. Counsel patients that burning/stinging is expected initially but improves with continued use. This is not an allergic reaction and does not require discontinuation unless severe.

Skin Atrophy Risk

No evidence of increased skin thinning with short-term TCS use (median 3 weeks), but longer-term use (6-60 months) shows increased atrophy risk even with mild-to-potent TCS 2. This makes TCIs the preferred long-term option for facial eczema maintenance.